Stephens & Co. analyst Jacob Johnson downgrades Lifecore Biomedical (NASDAQ:LFCR) from Overweight to Equal-Weight and lowers the price target from $11 to $2.
Stephens & Co. Downgrades Lifecore Biomedical to Equal-Weight, Lowers Price Target to $2
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.